» Articles » PMID: 27386438

Orosomucoid-1 Expression in Ameloblastoma Variants

Overview
Specialty Genetics
Date 2016 Jul 8
PMID 27386438
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Odontogenic tumors constitute a group of heterogeneous lesions of benign and malignant neoplasms with variable aggressiveness. Ameloblastomas are a group of benign but locally invasive neoplasms that occur in the jaws and are derived from epithelial elements of the tooth-forming apparatus. We previously described orosomucoid-1 protein expression in odontogenic myxomas. However, whether orosomucoid-1 is expressed in other odontogenic tumors remains unknown. Since orosomucoid-1 belongs to a group of acute-phase proteins and has many functions in health and disease, we identified and analyzed orosomucoid-1 expression in ameloblastoma variants and ameloblastic carcinoma using western blot and immunohistochemical techniques. Thirty cases of ameloblastoma were analyzed for orsomucoid-1; five specimens were fresh for western blot study (four benign ameloblastomas and one ameloblastic carcinoma), and 25 cases of benign ameloblastoma for immunohistochemical assays. Orosomucoid-1 was widely expressed in each tumor variant analyzed in this study, and differential orosomucoid-1 expression was observed between benign and malignant tumor. Orosomucoid-1 may play an important role in the behavior of ameloblastomas and influence the biology and development of the variants of this tumor.

Citing Articles

Estrogen weakens muscle endurance via estrogen receptor-p38 MAPK-mediated orosomucoid (ORM) suppression.

Sun Y, Qin Z, Wan J, Wang P, Yang Y, Yu J Exp Mol Med. 2018; 50(3):e463.

PMID: 29869624 PMC: 5898901. DOI: 10.1038/emm.2017.307.


Expression of parathyroid hormone related protein (PTHRP) in ameloblastomas.

Zeballos R, Bologna-Molina R, Pereira-Prado V, Villarroel-Dorrego M J Clin Exp Dent. 2018; 10(2):e172-e176.

PMID: 29670736 PMC: 5899800. DOI: 10.4317/jced.54222.

References
1.
Cheresh D, Haynes D, Distasio J . Interaction of an acute phase reactant, alpha 1-acid glycoprotein (orosomucoid), with the lymphoid cell surface: a model for non-specific immune suppression. Immunology. 1984; 51(3):541-8. PMC: 1454448. View

2.
Schmid K . Purification and properties of an alpha2-glycoprotein derived from normal human plasma. Biochim Biophys Acta. 1956; 21(2):399. DOI: 10.1016/0006-3002(56)90039-7. View

3.
Croce M, Price M, Segal-Eiras A . Association of a alpha1 acidic glycoprotein and squamous cell carcinoma of the head and neck. Pathol Oncol Res. 2001; 7(2):111-7. DOI: 10.1007/BF03032576. View

4.
Irmak S, Oliveira-Ferrer L, Singer B, Ergun S, Tilki D . Pro-angiogenic properties of orosomucoid (ORM). Exp Cell Res. 2009; 315(18):3201-9. DOI: 10.1016/j.yexcr.2009.07.024. View

5.
Bologna-Molina R, Mosqueda-Taylor A, Dominguez-Malagon H, Salazar-Rodriguez S, Tapia G, Gonzalez-Gonzalez R . Immunolocalization of VEGF-A and orosomucoid-1 in odontogenic myxoma. Rom J Morphol Embryol. 2015; 56(2):465-73. View